KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Leases (2019 - 2025)

Historic Operating Leases for Rigel Pharmaceuticals (RIGL) over the last 7 years, with Q3 2025 value amounting to $556000.0.

  • Rigel Pharmaceuticals' Operating Leases changed N/A to $556000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $556000.0, marking a year-over-year change of. This contributed to the annual value of $285000.0 for FY2023, which is 7067.9% down from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Operating Leases stood at $556000.0.
  • In the past 5 years, Rigel Pharmaceuticals' Operating Leases registered a high of $17.2 million during Q1 2021, and its lowest value of $100000.0 during Q1 2024.
  • In the last 5 years, Rigel Pharmaceuticals' Operating Leases had a median value of $780500.0 in 2021 and averaged $4.3 million.
  • In the last 5 years, Rigel Pharmaceuticals' Operating Leases tumbled by 9606.74% in 2021 and then soared by 76400.0% in 2025.
  • Rigel Pharmaceuticals' Operating Leases (Quarter) stood at $759000.0 in 2021, then rose by 28.06% to $972000.0 in 2022, then plummeted by 70.68% to $285000.0 in 2023, then plummeted by 64.91% to $100000.0 in 2024, then surged by 456.0% to $556000.0 in 2025.
  • Its last three reported values are $556000.0 in Q3 2025, $714000.0 for Q2 2025, and $864000.0 during Q1 2025.